Le Lézard
Classified in: Health, Science and technology
Subject: Merger/Acquisition

Eurofins Scientific Announces Acquisition of Beacon Discovery, Substantially Expanding Its Integrated Drug Discovery Capabilities and Expertise


Eurofins Scientific (EUFI.PA), a global scientific leader in bioanalytical testing announces the acquisition of Beacon Discovery, a preeminent drug discovery and contract research organization (CRO) focused on G-Protein Coupled Receptor (GPCR) research. Beacon Discovery joins Eurofins Discovery, a market leading CRO with the broadest portfolio of validated in vitro pharmacology, ADMET*, and chemistry services for integrated drug discovery solutions. The transaction is expected to close in the coming weeks upon fulfilment of customary closing conditions.

Eurofins acquired Beacon Discovery for its innovative approach, years of experience in drug discovery and development as well as their profound expertise in GPCR research, complemented by their unique compound library. The addition of Beacon Discovery supports Eurofins' strategy to be the partner of choice to the pharmaceutical industry, providing drug discovery experience, knowledge, and proven success in supporting the discovery and development of new therapeutics. Beacon Discovery significantly augments Eurofins Discovery's capabilities and innovative methods to support and accelerate drug discovery research and development and capitalize on the growing R&D outsourcing market.

Comment from Dr. Sunny Al-Shamma, Beacon Discovery's CEO: "Beacon Discovery is very excited to join Eurofins. Joining the Eurofins Discovery organisation expands our opportunity to continue our drug discovery efforts and provide integrated drug discovery services with the additive and complementary capabilities provided by Eurofins Discovery".

Comment from Dr. Gilles Martin, Eurofins' CEO: "Beacon Discovery adds the expertise in GPCR targets and drug discovery and development experience that will advance our offering in integrated drug discovery services for our clients. This transaction is another demonstration of Eurofins' commitment to provide the most comprehensive portfolio of laboratory services in the discovery pharmacology field which enjoys a strong outsourcing growth trend.

Notes to Editors:

For more information, please visit www.eurofins.com

About Eurofins ? the global leader in bio-analysis

Eurofins is Testing for Life. With over 50,000 staff across a network of more than 800 laboratories in over 50 countries, Eurofins' companies offer a portfolio of over 200,000 analytical methods.

Eurofins Shares are listed on Euronext Paris Stock Exchange.


These press releases may also interest you

at 08:05
Autobahn Therapeutics, a biotechnology company focused on restoring hope for people affected by CNS disorders, today announced the presentation of preclinical data of ABX-002, a CNS-penetrating prodrug that provides a balanced delivery of LL-340001,...

at 08:00
Branded Research Inc. is one of the world's leading market research communities. Branded Research works with companies to create Branded Surveys for their community of survey takers. The information collected from surveys helps companies collect...

at 07:00
Crypto Wealth Coach Seth Maniscalco has been selected for the cover of SHIFT Advanced Life Design Magazine. Seth Maniscalco, now a leading crypto investor and Blockchain expert started off as a navigational aid technician as an enlisted US Marine....

at 03:00
ONEMT, a leading mobile game developer, is celebrating Ramadan with its hit mobile real-time strategy game (RTS), Revenge of Sultans, from April 13 ? May 16. Taking the theme "#Enjoy Ramadan with the Revenge of Sultans", Revenge of Sultans will...

at 02:40
It is with profound sadness that Adobe shares the passing of the company's beloved co-founder, Dr. Charles Geschke. Dr. Geschke passed away on Friday, surrounded by his family. Dr. Geschke co-founded Adobe in 1982 with Dr. John Warnock, a colleague...

at 02:21
NASA astronaut Kate Rubins, along with Roscosmos cosmonauts Sergey Ryzhikov and Sergey Kud-Sverchkov, returned to Earth on Saturday, following six months living and working aboard the International Space Station....



News published on 18 february 2021 at 11:35 and distributed by: